A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.
Anthony S. Stein(University of Hohenheim), Ashish Bajel(The Royal Melbourne Hospital), Stéphane de Botton(Université Paris-Saclay), Kyle A. Jensen(Sanofi (United States)), Sylvain Garciaz(Centre National de la Recherche Scientifique), Gerwin Huls(University Medical Center Groningen), Mojca Jongen‐Lavrencic(Erasmus MC Cancer Institute), Gu Mi(Eli Lilly (United States)), David Avigan(Beth Israel Deaconess Medical Center), David C. de Leeuw(Dutch Cancer Society), C. Michel Zwaan(Princess Máxima Center), Timothy R. Wagenaar(AVEO Oncology (United States)), Abhishek Maiti(The University of Texas MD Anderson Cancer Center), Pinkal Desai(NewYork–Presbyterian Hospital), Nicolas Boissel(Inserm), Saskia Langemeijer(Radboud University Nijmegen), Shaun Fleming(Peter MacCallum Cancer Centre), Giovanni Abbadessa(Morristown Medical Center), Martha Arellano(Memorial Sloan Kettering Cancer Center)
Cited by 12
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k